Un derivado de 15(S)-15-metil PGF2α con mayor permeabilidad de membrana.1,2
15(S)-15-methyl Prostaglandin F2α methyl ester (CAS 35700-21-1) Referencias
1 Roseman, T.J., Biermacher, J.J., Bennett, R.M., et al. Design criteria for controlled release delivery systems of carboprost methyl. Journal of Controlled Release 3 25-37 (1986). 2 Halstead, G.W., Theis, D.L. Drug release testing of a prostaglandin containing controlled-release vaginal device: Development of a semi-automated method. J Pharm Sci 74 1086-1090 (1985). 3 Carlan, S.J., Gushwa, J.P., O'Brien, W.F., et al. Effect of intramuscular 15-methyl prostaglandin F2α after second-trimester delivery. Obstet Gynecol 89 5-9 (1997). 4 Lindblom, B., Källfelt, B., Hahlin, M., et al. Local prostaglandin F2α injection for termination of ectopic pregnancy. Lancet (1987). 5 Adaikan, P.G., Prasad, R.N.V., Kottegoda, S.R., et al. Effect of indomethacin on the injection-abortion interval of 15(S)15 methyl PGF2α-induced mid-trimester abortions - a randomized study. Prostaglandins Leukot Med 27 161-167 (1987).